__PRESENT__PRESENT
__PRESENT__PRESENT__PRESENT
__PRESENT
__PRESENT
__PRESENT
Enter your details to join our mobile app waitlist and receive early access to the Bell Direct App.
Join Bell Financial Group’s Senior Market Analyst Grady Wulff as she sat down with Dr. Liz Dallimore, CEO & MD of Argenica Therapeutics (ASX:AGN) to discuss the company’s lead drug candidate ARG-007, and its pathway to commercialisation to become the world’s first neuroprotective drug for the protection of brain cells post stroke or catastrophic brain injury.
In this interview, Liz covers:
Note: This interview was filmed on 24 September 2025.